Capillary leak syndrome prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Capillary leak syndrome}} | {{Capillary leak syndrome}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
A few [[prophylactic]] treatments have been tried with variable results, principally [[terbutaline]] and [[theophylline]]. | |||
==Prevention== | |||
The prevention of episodes of SCLS has involved two approaches. The first has long been identified with the Mayo Clinic and it recommends treatment with beta agonists such as [[theophylline]], [[terbutaline]] and montelukast sodium.<ref>{{cite journal |pmid=1580299 |year=1992 |last1=Droder |first1=RM |last2=Kyle |first2=RA |last3=Greipp |first3=PR |title=Control of systemic capillary leak syndrome with aminophylline and terbutaline |volume=92 |issue=5 |pages=523–6 |journal=The American Journal of Medicine |doi=10.1016/0002-9343(92)90749-2}}</ref> The second, more recent approach pioneered in France involves monthly intravenous infusions of [[intravenous immunoglobulin]] (IVIG), and the growing case-report evidence is encouraging.<ref>{{cite journal |pages=2184–7 |doi=10.1097/CCM.0b013e31817d7c71 |title=High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome |year=2008 |last1=Lambert |first1=Marc |last2=Launay |first2=David |last3=Hachulla |first3=Eric |last4=Morell-Dubois |first4=Sandrine |last5=Soland |first5=Vincent |last6=Queyrel |first6=Viviane |last7=Fourrier |first7=François |last8=Hatron |first8=Pierre-Yves |journal=Critical Care Medicine |volume=36 |issue=7 |pmid=18552679}}</ref><ref>{{cite journal |pages=e3–4 |doi=10.1016/j.amjmed.2009.09.034 |title=Immunoglobulins for Treatment of Systemic Capillary Leak Syndrome |year=2010 |last1=Abgueguen |first1=Pierre |last2=Chennebault |first2=Jean Marie |last3=Pichard |first3=Eric |journal=The American Journal of Medicine |volume=123 |issue=6 |pmid=20569743}}</ref><ref>{{cite journal|last1=Zipponi|first1=Manuel|last2=Eugster|first2=Roland|last3=Birrenbach|first3=Tanja|year=2011|title =High-dose intravenous immunoglobulins: A promising therapeutic approach for idiopathic systemic capillary leak syndrome|journal=BMJ Case Reports|volume=2011|doi=10.1136/bcr.12.2010.3599|url=http://casereports.bmj.com/content/2011/bcr.12.2010.3599.abstract}}</ref><ref name="pecker">{{cite journal |first1=Mark |last1=Pecker |first2=Michael |last2=Adams |first3=Walter |last3=Graham |title=The Systemic Capillary Leak Syndrome: Comment |journal=Annals of Internal Medicine |pmid=21893630 |pages=335 |doi=10.1059/0003-4819-155-5-201109060-00017 |year=2011 |volume=155 |issue=5}}</ref> | The prevention of episodes of SCLS has involved two approaches. The first has long been identified with the Mayo Clinic and it recommends treatment with beta agonists such as [[theophylline]], [[terbutaline]] and montelukast sodium.<ref>{{cite journal |pmid=1580299 |year=1992 |last1=Droder |first1=RM |last2=Kyle |first2=RA |last3=Greipp |first3=PR |title=Control of systemic capillary leak syndrome with aminophylline and terbutaline |volume=92 |issue=5 |pages=523–6 |journal=The American Journal of Medicine |doi=10.1016/0002-9343(92)90749-2}}</ref> The second, more recent approach pioneered in France involves monthly intravenous infusions of [[intravenous immunoglobulin]] (IVIG), and the growing case-report evidence is encouraging.<ref>{{cite journal |pages=2184–7 |doi=10.1097/CCM.0b013e31817d7c71 |title=High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome |year=2008 |last1=Lambert |first1=Marc |last2=Launay |first2=David |last3=Hachulla |first3=Eric |last4=Morell-Dubois |first4=Sandrine |last5=Soland |first5=Vincent |last6=Queyrel |first6=Viviane |last7=Fourrier |first7=François |last8=Hatron |first8=Pierre-Yves |journal=Critical Care Medicine |volume=36 |issue=7 |pmid=18552679}}</ref><ref>{{cite journal |pages=e3–4 |doi=10.1016/j.amjmed.2009.09.034 |title=Immunoglobulins for Treatment of Systemic Capillary Leak Syndrome |year=2010 |last1=Abgueguen |first1=Pierre |last2=Chennebault |first2=Jean Marie |last3=Pichard |first3=Eric |journal=The American Journal of Medicine |volume=123 |issue=6 |pmid=20569743}}</ref><ref>{{cite journal|last1=Zipponi|first1=Manuel|last2=Eugster|first2=Roland|last3=Birrenbach|first3=Tanja|year=2011|title =High-dose intravenous immunoglobulins: A promising therapeutic approach for idiopathic systemic capillary leak syndrome|journal=BMJ Case Reports|volume=2011|doi=10.1136/bcr.12.2010.3599|url=http://casereports.bmj.com/content/2011/bcr.12.2010.3599.abstract}}</ref><ref name="pecker">{{cite journal |first1=Mark |last1=Pecker |first2=Michael |last2=Adams |first3=Walter |last3=Graham |title=The Systemic Capillary Leak Syndrome: Comment |journal=Annals of Internal Medicine |pmid=21893630 |pages=335 |doi=10.1059/0003-4819-155-5-201109060-00017 |year=2011 |volume=155 |issue=5}}</ref> | ||
Revision as of 19:28, 28 January 2013
|
Capillary leak syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Capillary leak syndrome prevention On the Web |
|
American Roentgen Ray Society Images of Capillary leak syndrome prevention |
|
Risk calculators and risk factors for Capillary leak syndrome prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
A few prophylactic treatments have been tried with variable results, principally terbutaline and theophylline.
Prevention
The prevention of episodes of SCLS has involved two approaches. The first has long been identified with the Mayo Clinic and it recommends treatment with beta agonists such as theophylline, terbutaline and montelukast sodium.[1] The second, more recent approach pioneered in France involves monthly intravenous infusions of intravenous immunoglobulin (IVIG), and the growing case-report evidence is encouraging.[2][3][4][5]
A recent review of clinical experience with 28 European SCLS patients suggests that either prophylactic treatment may reduce the frequency and severity of attacks and may improve survival.[6]
References
- ↑ Droder, RM; Kyle, RA; Greipp, PR (1992). "Control of systemic capillary leak syndrome with aminophylline and terbutaline". The American Journal of Medicine. 92 (5): 523–6. doi:10.1016/0002-9343(92)90749-2. PMID 1580299.
- ↑ Lambert, Marc; Launay, David; Hachulla, Eric; Morell-Dubois, Sandrine; Soland, Vincent; Queyrel, Viviane; Fourrier, François; Hatron, Pierre-Yves (2008). "High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome". Critical Care Medicine. 36 (7): 2184–7. doi:10.1097/CCM.0b013e31817d7c71. PMID 18552679.
- ↑ Abgueguen, Pierre; Chennebault, Jean Marie; Pichard, Eric (2010). "Immunoglobulins for Treatment of Systemic Capillary Leak Syndrome". The American Journal of Medicine. 123 (6): e3–4. doi:10.1016/j.amjmed.2009.09.034. PMID 20569743.
- ↑ Zipponi, Manuel; Eugster, Roland; Birrenbach, Tanja (2011). "High-dose intravenous immunoglobulins: A promising therapeutic approach for idiopathic systemic capillary leak syndrome". BMJ Case Reports. 2011. doi:10.1136/bcr.12.2010.3599.
- ↑ Pecker, Mark; Adams, Michael; Graham, Walter (2011). "The Systemic Capillary Leak Syndrome: Comment". Annals of Internal Medicine. 155 (5): 335. doi:10.1059/0003-4819-155-5-201109060-00017. PMID 21893630.
- ↑ Gousseff, Marie; Arnaud, Laurent; Lambert, Marc; Hot, Arnaud; Hamidou, Mohamed; Duhaut, Pierre; Papo, Thomas; Soubrier, Martin; Ruivard, Marc (2011). "The Systemic Capillary Leak Syndrome: A Case Series of 28 Patients From a European Registry". Annals of Internal Medicine. 154 (7): 464–71. doi:10.1059/0003-4819-154-7-201104050-00004. PMID 21464348.